[S02DA03, antipyrine, The therapeutic efficacy of Terazosin can be decreased when used in combination with Antipyrine.]
[B01AD01, streptokinase, The risk or severity of adverse effects can be increased when Streptokinase is combined with Terazosin.]
[M01AB02, sulindac, The therapeutic efficacy of Terazosin can be decreased when used in combination with Sulindac.]
[M01AX04, apazone, The therapeutic efficacy of Terazosin can be decreased when used in combination with Azapropazone.]
[R03CC03, terbutaline, The therapeutic efficacy of Terbutaline can be decreased when used in combination with Terazosin.]
[N05AE05, lurasidone, Terazosin may increase the hypotensive activities of Lurasidone.]
[N04BC07, apomorphine, The risk or severity of adverse effects can be increased when Apomorphine is combined with Terazosin.]
[L04AX02, thalidomide, The risk or severity of adverse effects can be increased when Thalidomide is combined with Terazosin.]
[N05CA19, thiopental, Thiopental may increase the hypotensive activities of Terazosin.]
[N05AB08, thioproperazine, Terazosin may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Thioproperazine.]
[N05AC02, thioridazine, Thioridazine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Terazosin.]
[G04BE06, moxisylyte, Moxisylyte may decrease the antihypertensive activities of Terazosin.]
[S01ED01, timolol, Timolol may increase the orthostatic hypotensive activities of Terazosin.]
[M02AX02, tolazoline, Tolazoline may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Terazosin.]
[M02AA21, tolmetin, The therapeutic efficacy of Terazosin can be decreased when used in combination with Tolmetin.]
[N06AF04, tranylcypromine, Tranylcypromine may increase the hypotensive activities of Terazosin.]
[N06AX05, trazodone, Trazodone may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Terazosin.]
[L01XF01, tretinoin, The risk or severity of adverse effects can be increased when Tretinoin is combined with Terazosin.]
[C03DB02, triamterene, The risk or severity of adverse effects can be increased when Triamterene is combined with Terazosin.]
[C03AA06, trichlormethiazide, The therapeutic efficacy of Terazosin can be increased when used in combination with Trichlormethiazide.]
[N05AB06, trifluoperazine, Trifluoperazine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Terazosin.]
[A03AA05, trimebutine, The risk or severity of hypotension can be increased when Terazosin is combined with Trimebutine.]
[S01ED04, metipranolol, Terazosin may increase the hypotensive activities of Metipranolol.]
[N03AC02, trimethadione, The risk or severity of hypotension can be increased when Terazosin is combined with Trimethadione.]
[C02BA01, trimethaphan, Trimethaphan may increase the hypotensive activities of Terazosin.]
[N06AA06, trimipramine, Trimipramine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Terazosin.]
[N06AX24, vilazodone, Vilazodone may decrease the antihypertensive activities of Terazosin.]
[C09CA09, azilsartan medoxomil, Terazosin may increase the hypotensive activities of Azilsartan medoxomil.]
[J05AP03, boceprevir, Boceprevir may increase the hypotensive activities of Terazosin.]
[R03AC18, indacaterol, The therapeutic efficacy of Indacaterol can be decreased when used in combination with Terazosin.]
[C08DA01, verapamil, Verapamil may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Terazosin.]
[C04AX07, vincamine, Terazosin may increase the hypotensive activities of Vincamine.]
[N01AX15, xenon, Xenon may decrease the antihypertensive activities of Terazosin.]
[C03BA10, xipamide, Terazosin may increase the hypotensive activities of Xipamide.]
[N05AF05, zuclopenthixol, Terazosin may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Zuclopenthixol.]
[N05AE04, ziprasidone, Ziprasidone may increase the antihypertensive activities of Terazosin.]
[N02BA01, aspirin, Acetylsalicylic acid may decrease the antihypertensive activities of Terazosin.]
[C07AB03, atenolol, Atenolol may increase the orthostatic hypotensive activities of Terazosin.]
[L01FA01, rituximab, Terazosin may increase the hypotensive activities of Rituximab.]
[S01FA01, atropine, Atropine may decrease the antihypertensive activities of Terazosin.]
[G04BE10, avanafil, Terazosin may increase the hypotensive activities of Avanafil.]
[M03BX01, baclofen, The risk or severity of adverse effects can be increased when Baclofen is combined with Terazosin.]
[G04BD12, mirabegron, The therapeutic efficacy of Mirabegron can be decreased when used in combination with Terazosin.]
[C01CA18, octopamine, The therapeutic efficacy of Octopamine can be decreased when used in combination with Terazosin.]
[N05CA04, barbital, Barbital may increase the hypotensive activities of Terazosin.]
[S01GA07, brimonidine, Brimonidine may increase the antihypertensive activities of Terazosin.]
[N04BD02, rasagiline, Rasagiline may increase the hypotensive activities of Terazosin.]
[C08CA13, lercanidipine, The risk or severity of hypotension can be increased when Terazosin is combined with Lercanidipine.]
[N02CC03, zolmitriptan, Zolmitriptan may decrease the antihypertensive activities of Terazosin.]
[N01AA01, ethyl ether, Diethyl ether may decrease the antihypertensive activities of Terazosin.]
[G04BE03, sildenafil, The risk or severity of hypotension and syncope can be increased when Sildenafil is combined with Terazosin.]
[C04AX11, bencyclane, The risk or severity of hypotension can be increased when Terazosin is combined with Bencyclane.]
[C03AA01, bendroflumethiazide, The therapeutic efficacy of Terazosin can be increased when used in combination with Bendroflumethiazide.]
[N02BA10, benorilate, The therapeutic efficacy of Terazosin can be decreased when used in combination with Benorilate.]
[A10BK02, canagliflozin, The risk or severity of adverse effects can be increased when Terazosin is combined with Canagliflozin.]
[M01AH01, celecoxib, The therapeutic efficacy of Terazosin can be decreased when used in combination with Celecoxib.]
[N02CC02, naratriptan, Naratriptan may decrease the antihypertensive activities of Terazosin.]
[R02AX03, benzydamine, The therapeutic efficacy of Terazosin can be decreased when used in combination with Benzydamine.]
[C08EA02, bepridil, The risk or severity of hypotension can be increased when Terazosin is combined with Bepridil.]
[C02KX05, riociguat, Terazosin may increase the hypotensive activities of Riociguat.]
[C02KX04, macitentan, Terazosin may increase the hypotensive activities of Macitentan.]
[N06AX26, vortioxetine, Vortioxetine may decrease the antihypertensive activities of Terazosin.]
[A10BK01, dapagliflozin, The risk or severity of adverse effects can be increased when Terazosin is combined with Dapagliflozin.]
[C01CA27, droxidopa, The therapeutic efficacy of Droxidopa can be decreased when used in combination with Terazosin.]
[C07AB04, acebutolol, Acebutolol may increase the orthostatic hypotensive activities of Terazosin.]
[S01ED02, betaxolol, Betaxolol may increase the orthostatic hypotensive activities of Terazosin.]
[C02CC01, bethanidine, The therapeutic efficacy of Bethanidine can be decreased when used in combination with Terazosin.]
[A10BK03, empagliflozin, The risk or severity of adverse effects can be increased when Terazosin is combined with Empagliflozin.]
[R03AC19, olodaterol, The therapeutic efficacy of Olodaterol can be decreased when used in combination with Terazosin.]
[S01EE02, unoprostone, Terazosin may increase the hypotensive activities of Unoprostone.]
[N05AA04, acepromazine, Terazosin may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Acepromazine.]
[N06AX11, mirtazapine, Mirtazapine may decrease the antihypertensive activities of Terazosin.]
[N05AX16, brexpiprazole, Terazosin may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Brexpiprazole.]
[G02CX02, flibanserin, Flibanserin may decrease the antihypertensive activities of Terazosin.]
[N05AX15, cariprazine, Cariprazine may decrease the antihypertensive activities of Terazosin.]
[M02AA25, aceclofenac, The therapeutic efficacy of Terazosin can be decreased when used in combination with Aceclofenac.]
[M01AB11, acemetacin, The therapeutic efficacy of Terazosin can be decreased when used in combination with Acemetacin.]
[B01AC27, selexipag, Terazosin may increase the hypotensive activities of Selexipag.]
[G04CA01, alfuzosin, Terazosin may increase the hypotensive activities of Alfuzosin.]
[M01AE16, alminoprofen, The therapeutic efficacy of Terazosin can be decreased when used in combination with Alminoprofen.]
[N04BC01, bromocriptine, Terazosin may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Bromocriptine.]
[N06AA19, amineptin, Amineptine may decrease the antihypertensive activities of Terazosin.]
[C08CA01, amlodipine, The risk or severity of hypotension can be increased when Terazosin is combined with Amlodipine.]
[C03CA02, bumetanide, The risk or severity of adverse effects can be increased when Bumetanide is combined with Terazosin.]
[N01BB01, bupivacaine, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Terazosin.]
[C07AA19, bupranolol, Bupranolol may increase the orthostatic hypotensive activities of Terazosin.]
[N05BE01, buspirone, Buspirone may decrease the antihypertensive activities of Terazosin.]
[L01XX27, arsenic trioxide, The risk or severity of adverse effects can be increased when Terazosin is combined with Arsenic trioxide.]
[A07EC04, balsalazide, The therapeutic efficacy of Terazosin can be decreased when used in combination with Balsalazide.]
[R03CC12, bambuterol, The therapeutic efficacy of Bambuterol can be decreased when used in combination with Terazosin.]
[C09AA07, benazepril, Benazepril may increase the hypotensive activities of Terazosin.]
[J01XX08, linezolid, Linezolid may increase the hypotensive activities of Terazosin.]
[N04BD03, safinamide, Safinamide may increase the hypotensive activities of Terazosin.]
[C07AB07, bisoprolol, Bisoprolol may increase the orthostatic hypotensive activities of Terazosin.]
[R03AC17, bitolterol, The therapeutic efficacy of Bitolterol can be decreased when used in combination with Terazosin.]
[C07AA17, bopindolol, Bopindolol may increase the orthostatic hypotensive activities of Terazosin.]
[C01DX19, nesiritide, The risk or severity of adverse effects can be increased when Terazosin is combined with Nesiritide.]
[C04AX20, buflomedil, Buflomedil may decrease the antihypertensive activities of Terazosin.]
[M01AB07, bumadizone, The therapeutic efficacy of Terazosin can be decreased when used in combination with Bumadizone.]
[N06AA15, butriptyline, Butriptyline may decrease the antihypertensive activities of Terazosin.]
[C09AA01, captopril, Terazosin may increase the hypotensive activities of Captopril.]
[C07AG02, carvedilol, Carvedilol may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Terazosin.]
[B02BX09, fostamatinib, The risk or severity of hypotension and syncope can be increased when Fostamatinib is combined with Terazosin.]
[N03AX24, cannabidiol, Cannabidiol may decrease the antihypertensive activities of Terazosin.]
[C07AB08, celiprolol, The therapeutic efficacy of Celiprolol can be decreased when used in combination with Terazosin.]
[M01AC05, lornoxicam, The therapeutic efficacy of Terazosin can be decreased when used in combination with Lornoxicam.]
[C09AA08, cilazapril, Terazosin may increase the hypotensive activities of Cilazapril.]
[A03FA08, cinitapride, Cinitapride may decrease the antihypertensive activities of Terazosin.]
[S01ED05, carteolol, Carteolol may increase the hypotensive activities of Terazosin.]
[L04AA42, siponimod, Siponimod may decrease the antihypertensive activities of Terazosin.]
[N06BA14, solriamfetol, Solriamfetol may decrease the antihypertensive activities of Terazosin.]
[C09CA06, candesartan, Terazosin may increase the hypotensive activities of Candesartan.]
[C03BX03, cicletanine, Terazosin may increase the hypotensive activities of Cicletanine.]
[C03AA09, cyclothiazide, The therapeutic efficacy of Terazosin can be increased when used in combination with Cyclothiazide.]
[G04BE04, yohimbine, Yohimbine may decrease the antihypertensive activities of Terazosin.]
[N02CC07, frovatriptan, Frovatriptan may decrease the antihypertensive activities of Terazosin.]
[G04CB02, dutasteride, Dutasteride may decrease the antihypertensive activities of Terazosin.]
[N02CC06, eletriptan, Eletriptan may decrease the antihypertensive activities of Terazosin.]
[M01AH02, rofecoxib, The therapeutic efficacy of Terazosin can be decreased when used in combination with Rofecoxib.]
[C08CA16, clevidipine, The risk or severity of hypotension can be increased when Terazosin is combined with Clevidipine.]
[C01BD07, dronedarone, Terazosin may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Dronedarone.]
[C02AA06, methoserpidine, Terazosin may increase the hypotensive activities of Methoserpidine.]
[N04BX04, opicapone, The risk or severity of adverse effects can be increased when Terazosin is combined with Opicapone.]
[C01CA14, dopexamine, The therapeutic efficacy of Dopexamine can be decreased when used in combination with Terazosin.]
[M01AC04, droxicam, The therapeutic efficacy of Terazosin can be decreased when used in combination with Droxicam.]
[L01EX22, selpercatinib, Selpercatinib may decrease the antihypertensive activities of Terazosin.]
[M02AA27, dexketoprofen, The therapeutic efficacy of Terazosin can be decreased when used in combination with Dexketoprofen.]
[C08CA17, levamlodipine, The risk or severity of hypotension can be increased when Terazosin is combined with Levamlodipine.]
[C03AA04, chlorothiazide, The therapeutic efficacy of Terazosin can be increased when used in combination with Chlorothiazide.]
[N05AA01, chlorpromazine, Chlorpromazine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Terazosin.]
[C03BA04, chlorthalidone, Chlorthalidone may increase the hypotensive activities of Terazosin.]
[N02BA07, ethenzamide, The therapeutic efficacy of Terazosin can be decreased when used in combination with Ethenzamide.]
[N06BX18, vinpocetine, The risk or severity of hypotension can be increased when Terazosin is combined with Vinpocetine.]
[M01AB08, etodolac, The therapeutic efficacy of Terazosin can be decreased when used in combination with Etodolac.]
[M02AA06, etofenamate, The therapeutic efficacy of Terazosin can be decreased when used in combination with Etofenamate.]
[L01FX21, naxitamab, Naxitamab may decrease the antihypertensive activities of Terazosin.]
[C01DX22, vericiguat, The risk or severity of adverse effects can be increased when Terazosin is combined with Vericiguat.]
[M01AE05, fenbufen, The therapeutic efficacy of Terazosin can be decreased when used in combination with Fenbufen.]
[C01CA19, fenoldopam, Fenoldopam may increase the hypotensive activities of Terazosin.]
[N06BA08, fenozolone, Fenozolone may decrease the antihypertensive activities of Terazosin.]
[G04CB01, finasteride, Finasteride may decrease the antihypertensive activities of Terazosin.]
[R03CC15, formoterol, The therapeutic efficacy of Formoterol can be decreased when used in combination with Terazosin.]
[N01AB05, trichloroethylene, Trichloroethylene may decrease the antihypertensive activities of Terazosin.]
[H04AA02, dasiglucagon, Terazosin may increase the hypotensive activities of Dasiglucagon.]
[N07CA02, cinnarizine, The risk or severity of hypotension can be increased when Terazosin is combined with Cinnarizine.]
[R03CC13, clenbuterol, The therapeutic efficacy of Clenbuterol can be decreased when used in combination with Terazosin.]
[N01BB10, levobupivacaine, The risk or severity of adverse effects can be increased when Levobupivacaine is combined with Terazosin.]
[N06AA04, clomipramine, Clomipramine may decrease the antihypertensive activities of Terazosin.]
[S01EA04, clonidine, The risk or severity of hypotension can be increased when Clonidine is combined with Terazosin.]
[N05AH02, clozapine, Clozapine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Terazosin.]
[C02KB01, metyrosine, Metyrosine may increase the hypotensive activities of Terazosin.]
[M01AX13, proquazone, The therapeutic efficacy of Terazosin can be decreased when used in combination with Proquazone.]
[N01AB07, desflurane, Desflurane may decrease the antihypertensive activities of Terazosin.]
[C04AX28, ifenprodil, Ifenprodil may decrease the antihypertensive activities of Terazosin.]
[N02BA16, imidazole-2-hydroxybenzoate, The therapeutic efficacy of Terazosin can be decreased when used in combination with Imidazole salicylate.]
[B01AC10, indobufen, The therapeutic efficacy of Terazosin can be decreased when used in combination with Indobufen.]
[M01AH03, valdecoxib, The therapeutic efficacy of Terazosin can be decreased when used in combination with Valdecoxib.]
[A03AX10, isometheptene, The therapeutic efficacy of Isometheptene can be decreased when used in combination with Terazosin.]
[N02CC05, almotriptan, Almotriptan may decrease the antihypertensive activities of Terazosin.]
[M01AH04, parecoxib, The therapeutic efficacy of Terazosin can be decreased when used in combination with Parecoxib.]
[M01AA06, kebuzone, The therapeutic efficacy of Terazosin can be decreased when used in combination with Kebuzone.]
[S01EE04, travoprost, Travoprost may increase the hypotensive activities of Terazosin.]
[S01EE03, bimatoprost, Bimatoprost may increase the hypotensive activities of Terazosin.]
[C08CA09, lacidipine, Terazosin may increase the hypotensive activities of Lacidipine.]
[N07BC04, lofexidine, The therapeutic efficacy of Lofexidine can be decreased when used in combination with Terazosin.]
[M01AB09, lonazolac, The therapeutic efficacy of Terazosin can be decreased when used in combination with Lonazolac.]
[M02AA31, loxoprofen, The therapeutic efficacy of Terazosin can be decreased when used in combination with Loxoprofen.]
[C09AA03, lisinopril, Lisinopril may increase the hypotensive activities of Terazosin.]
[C08CA11, manidipine, The risk or severity of hypotension can be increased when Terazosin is combined with Manidipine.]
[A08AA09, mefenorex, Mefenorex may decrease the antihypertensive activities of Terazosin.]
[C07AA14, mepindolol, Mepindolol may increase the orthostatic hypotensive activities of Terazosin.]
[C04AX01, cyclandelate, The risk or severity of hypotension can be increased when Terazosin is combined with Cyclandelate.]
[R03CB02, methoxyphenamine, The therapeutic efficacy of Terazosin can be decreased when used in combination with Methoxyphenamine.]
[C03DA04, eplerenone, Eplerenone may increase the hypotensive activities of Terazosin.]
[C03AA07, cyclopenthiazide, The therapeutic efficacy of Terazosin can be increased when used in combination with Cyclopenthiazide.]
[N06AX07, minaprine, Minaprine may increase the hypotensive activities of Terazosin.]
[S01XA18, cyclosporine, Cyclosporine may decrease the antihypertensive activities of Terazosin.]
[N06AG02, moclobemide, Moclobemide may increase the hypotensive activities of Terazosin.]
[C09AA13, moexipril, Moexipril may increase the hypotensive activities of Terazosin.]
[M02AA02, mofebutazone, The therapeutic efficacy of Terazosin can be decreased when used in combination with Mofebutazone.]
[M01AX22, morniflumate, The therapeutic efficacy of Terazosin can be decreased when used in combination with Morniflumate.]
[C03XA02, conivaptan, The risk or severity of adverse effects can be increased when Conivaptan is combined with Terazosin.]
[C02AC05, moxonidine, The therapeutic efficacy of Moxonidine can be decreased when used in combination with Terazosin.]
[G04BE09, vardenafil, The risk or severity of hypotension and syncope can be increased when Vardenafil is combined with Terazosin.]
[M01AH05, etoricoxib, The therapeutic efficacy of Terazosin can be decreased when used in combination with Etoricoxib.]
[C02CC04, debrisoquin, Terazosin may increase the hypotensive activities of Debrisoquine.]
[A04AD11, nabilone, The risk or severity of adverse effects can be increased when Nabilone is combined with Terazosin.]
[M01AX01, nabumetone, The therapeutic efficacy of Terazosin can be decreased when used in combination with Nabumetone.]
[C07AB12, nebivolol, The therapeutic efficacy of Nebivolol can be decreased when used in combination with Terazosin.]
[N06AX06, nefazodone, Nefazodone may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Terazosin.]
[C01DX16, nicorandil, Nicorandil may increase the hypotensive activities of Terazosin.]
[C01CA23, theodrenaline, Terazosin may decrease the hypertensive activities of Theodrenaline.]
[C01CA05, norfenefrine, The therapeutic efficacy of Norfenefrine can be decreased when used in combination with Terazosin.]
[G04BD08, solifenacin, Solifenacin may decrease the antihypertensive activities of Terazosin.]
[A07EC03, olsalazine, The therapeutic efficacy of Terazosin can be decreased when used in combination with Olsalazine.]
[N06AA01, desipramine, Desipramine may decrease the antihypertensive activities of Terazosin.]
[H01BA02, desmopressin, Desmopressin may decrease the antihypertensive activities of Terazosin.]
[C09XA02, aliskiren, Terazosin may increase the hypotensive activities of Aliskiren.]
[M01AE12, oxaprozin, The therapeutic efficacy of Terazosin can be decreased when used in combination with Oxaprozin.]
[N06BA02, dextroamphetamine, The therapeutic efficacy of Terazosin can be decreased when used in combination with Amphetamine.]
[V03AH01, diazoxide, Diazoxide may increase the hypotensive activities of Terazosin.]
[N06AA08, dibenzepin, Dibenzepin may decrease the antihypertensive activities of Terazosin.]
[S01EC02, dichlorphenamide, The risk or severity of adverse effects can be increased when Diclofenamide is combined with Terazosin.]
[S01BC03, diclofenac, The therapeutic efficacy of Terazosin can be decreased when used in combination with Diclofenac.]
[C02DG01, pinacidil, Terazosin may increase the hypotensive activities of Pinacidil.]
[A03AX04, pinaverium, The risk or severity of hypotension can be increased when Terazosin is combined with Pinaverium.]
[N05AD05, pipamperone, The risk or severity of adverse effects can be increased when Terazosin is combined with Pipamperone.]
[R03CC07, pirbuterol, The therapeutic efficacy of Pirbuterol can be decreased when used in combination with Terazosin.]
[A08AA03, diethylpropion, The therapeutic efficacy of Terazosin can be decreased when used in combination with Diethylpropion.]
[C08CA03, isradipine, The risk or severity of hypotension can be increased when Terazosin is combined with Isradipine.]
[N02BA11, diflunisal, The therapeutic efficacy of Terazosin can be decreased when used in combination with Diflunisal.]
[C02DB01, dihydralazine, Terazosin may increase the hypotensive activities of Dihydralazine.]
[C04AE04, dihydroergocristine, Dihydroergocristine may decrease the antihypertensive activities of Terazosin.]
[N02CA01, dihydroergotamine, Dihydroergotamine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Terazosin.]
[B01AC21, treprostinil, Treprostinil may increase the hypotensive activities of Terazosin.]
[C08DB01, diltiazem, The risk or severity of hypotension can be increased when Terazosin is combined with Diltiazem.]
[R03CC08, procaterol, The therapeutic efficacy of Procaterol can be decreased when used in combination with Terazosin.]
[N02BB04, propyphenazone, The therapeutic efficacy of Terazosin can be decreased when used in combination with Propyphenazone.]
[M01AB14, proglumetacin, The therapeutic efficacy of Terazosin can be decreased when used in combination with Proglumetacin.]
[C09AA06, quinapril, Quinapril may increase the hypotensive activities of Terazosin.]
[B01AC07, dipyridamole, The risk or severity of hypotension and syncope can be increased when Dipyridamole is combined with Terazosin.]
[N06BA11, dexmethylphenidate, Dexmethylphenidate may decrease the antihypertensive activities of Terazosin.]
[N06AA23, quinupramine, Quinupramine may decrease the antihypertensive activities of Terazosin.]
[C09AA05, ramipril, Ramipril may increase the hypotensive activities of Terazosin.]
[R03CC14, reproterol, The therapeutic efficacy of Reproterol can be decreased when used in combination with Terazosin.]
[N05AX08, risperidone, Terazosin may increase the hypotensive activities of Risperidone.]
[N01BB09, ropivacaine, The risk or severity of adverse effects can be increased when Ropivacaine is combined with Terazosin.]
[G04BE08, tadalafil, The risk or severity of hypotension and syncope can be increased when Tadalafil is combined with Terazosin.]
[S01BC05, ketorolac, The therapeutic efficacy of Terazosin can be decreased when used in combination with Ketorolac.]
[C02KX02, ambrisentan, Terazosin may increase the hypotensive activities of Ambrisentan.]
[N02BA06, salsalate, The therapeutic efficacy of Terazosin can be decreased when used in combination with Salsalate.]
[R03AC12, salmeterol, The therapeutic efficacy of Salmeterol can be decreased when used in combination with Terazosin.]
[C01CA07, dobutamine, The therapeutic efficacy of Dobutamine can be decreased when used in combination with Terazosin.]
[C01CA04, dopamine, Dopamine may decrease the antihypertensive activities of Terazosin.]
[N06AA16, dothiepin, Dosulepin may decrease the antihypertensive activities of Terazosin.]
[R07AB01, doxapram, Doxapram may decrease the antihypertensive activities of Terazosin.]
[N06AA12, doxepin, Doxepin may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Terazosin.]
[N01AB08, sevoflurane, Sevoflurane may decrease the antihypertensive activities of Terazosin.]
[N05AD08, droperidol, Droperidol may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Terazosin.]
[C09AA11, spirapril, Terazosin may increase the hypotensive activities of Spirapril.]
[N02CC01, sumatriptan, Sumatriptan may decrease the antihypertensive activities of Terazosin.]
[C07AB13, talinolol, Talinolol may increase the orthostatic hypotensive activities of Terazosin.]
[M01AC02, tenoxicam, The therapeutic efficacy of Terazosin can be decreased when used in combination with Tenoxicam.]
[M01AG01, mefenamic acid, The therapeutic efficacy of Terazosin can be decreased when used in combination with Mefenamic acid.]
[G04BD05, terodiline, The risk or severity of hypotension can be increased when Terazosin is combined with Terodiline.]
[C07AA16, tertatolol, Tertatolol may increase the orthostatic hypotensive activities of Terazosin.]
[S01GA02, tetrahydrozoline, The therapeutic efficacy of Tetryzoline can be decreased when used in combination with Terazosin.]
[N06AX14, tianeptine, Tianeptine may decrease the antihypertensive activities of Terazosin.]
[C09AA02, enalapril, Enalapril may increase the hypotensive activities of Terazosin.]
[M01AG02, tolfenamic acid, The therapeutic efficacy of Terazosin can be decreased when used in combination with Tolfenamic acid.]
[N06AG03, toloxatone, Toloxatone may increase the hypotensive activities of Terazosin.]
[N06BA09, atomoxetine, Atomoxetine may decrease the antihypertensive activities of Terazosin.]
[C03CA04, torsemide, Torasemide may increase the hypotensive activities of Terazosin.]
[R01AA09, tramazoline, Tramazoline may decrease the antihypertensive activities of Terazosin.]
[C09AA10, trandolapril, Trandolapril may increase the hypotensive activities of Terazosin.]
[R03CC11, tulobuterol, The therapeutic efficacy of Tulobuterol can be decreased when used in combination with Terazosin.]
[C02CA06, urapidil, Terazosin may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Urapidil.]
[S01FB02, ephedrine, The therapeutic efficacy of Ephedrine can be decreased when used in combination with Terazosin.]
[C01CX07, xamoterol, The therapeutic efficacy of Xamoterol can be decreased when used in combination with Terazosin.]
[S01GA03, xylometazoline, The therapeutic efficacy of Xylometazoline can be decreased when used in combination with Terazosin.]
[C08CA12, mepirodipine, Terazosin may increase the antihypertensive activities of Barnidipine.]
[S01EA01, epinephrine, The therapeutic efficacy of Epinephrine can be decreased when used in combination with Terazosin.]
[C09AA15, zofenopril, Terazosin may increase the hypotensive activities of Zofenopril.]
[M01AB04, zomepirac, The therapeutic efficacy of Terazosin can be decreased when used in combination with Zomepirac.]
[N03AX15, zonisamide, The risk or severity of hypotension can be increased when Terazosin is combined with Zonisamide.]
[C02AC02, guanfacine, The therapeutic efficacy of Guanfacine can be decreased when used in combination with Terazosin.]
[B01AC11, iloprost, Iloprost may increase the hypotensive activities of Terazosin.]
[G02AB03, ergonovine, The therapeutic efficacy of Ergometrine can be decreased when used in combination with Terazosin.]
[C04AE01, ergoloid mesylates, USP, Ergoloid mesylate may decrease the antihypertensive activities of Terazosin.]
[N02CA02, ergotamine, Ergotamine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Terazosin.]
[C01CA15, gepefrine, The therapeutic efficacy of Terazosin can be decreased when used in combination with Gepefrine.]
[V03AF05, amifostine, Terazosin may increase the hypotensive activities of Amifostine.]
[N03AD01, ethosuximide, The risk or severity of hypotension can be increased when Terazosin is combined with Ethosuximide.]
[M01AC06, meloxicam, The therapeutic efficacy of Terazosin can be decreased when used in combination with Meloxicam.]
[C01CA01, etilefrine, The therapeutic efficacy of Etilefrine can be decreased when used in combination with Terazosin.]
[N01AX07, etomidate, The therapeutic efficacy of Etomidate can be decreased when used in combination with Terazosin.]
[C08CA02, felodipine, The risk or severity of hypotension can be increased when Terazosin is combined with Felodipine.]
[C08EA01, fendiline, The risk or severity of hypotension can be increased when Terazosin is combined with Fendiline.]
[M01AE04, fenoprofen, The therapeutic efficacy of Terazosin can be decreased when used in combination with Fenoprofen.]
[R03CC04, fenoterol, The therapeutic efficacy of Fenoterol can be decreased when used in combination with Terazosin.]
[N02AB03, fentanyl, Fentanyl may decrease the antihypertensive activities of Terazosin.]
[R03CC02, albuterol, The therapeutic efficacy of Salbutamol can be decreased when used in combination with Terazosin.]
[L01BB06, clofarabine, The risk or severity of adverse effects can be increased when Clofarabine is combined with Terazosin.]
[N02BG04, floctafenine, The therapeutic efficacy of Terazosin can be decreased when used in combination with Floctafenine.]
[N07CA03, flunarizine, The risk or severity of hypotension can be increased when Terazosin is combined with Flunarizine.]
[N06AA14, melitracen, Melitracen may decrease the antihypertensive activities of Terazosin.]
[V03AZ01, ethanol, Ethanol may increase the hypotensive activities of Terazosin.]
[N05AF01, flupenthixol, Flupentixol may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Terazosin.]
[S01BC04, flurbiprofen, The therapeutic efficacy of Terazosin can be decreased when used in combination with Flurbiprofen.]
[N05AG01, fluspirilene, The risk or severity of hypotension can be increased when Terazosin is combined with Fluspirilene.]
[N06BX17, adrafinil, The therapeutic efficacy of Adrafinil can be decreased when used in combination with Terazosin.]
[G01AX06, furazolidone, Furazolidone may increase the hypotensive activities of Terazosin.]
[C03CA01, furosemide, Furosemide may increase the hypotensive activities of Terazosin.]
[C08DA02, gallopamil, The risk or severity of hypotension can be increased when Terazosin is combined with Gallopamil.]
[N03AA04, barbexaclone, Barbexaclone may increase the hypotensive activities of Terazosin.]
[N04BC06, cabergoline, Cabergoline may decrease the antihypertensive activities of Terazosin.]
[N03AD03, methsuximide, The risk or severity of hypotension can be increased when Terazosin is combined with Methsuximide.]
[N01AH02, alfentanil, Alfentanil may decrease the antihypertensive activities of Terazosin.]
[N05CM18, dexmedetomidine, The therapeutic efficacy of Dexmedetomidine can be decreased when used in combination with Terazosin.]
[C05AE01, nitroglycerin, Nitroglycerin may increase the hypotensive activities of Terazosin.]
[C02CA04, doxazosin, Doxazosin may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Terazosin.]
[C07AB09, esmolol, Esmolol may increase the orthostatic hypotensive activities of Terazosin.]
[C09AA09, fosinopril, Fosinopril may increase the hypotensive activities of Terazosin.]
[S01EX01, guanethidine, Terazosin may increase the hypotensive activities of Guanethidine.]
[N01AB01, halothane, Halothane may decrease the antihypertensive activities of Terazosin.]
[N05AH04, quetiapine, Quetiapine may increase the hypotensive activities of Terazosin.]
[C09CA01, losartan, Losartan may increase the hypotensive activities of Terazosin.]
[A07EC02, mesalamine, The therapeutic efficacy of Terazosin can be decreased when used in combination with Mesalazine.]
[N05CA16, hexobarbital, Hexobarbital may increase the hypotensive activities of Terazosin.]
[R03CC05, hexoprenaline, The therapeutic efficacy of Hexoprenaline can be decreased when used in combination with Terazosin.]
[C08CA10, nilvadipine, The risk or severity of hypotension can be increased when Terazosin is combined with Nilvadipine.]
[M02AA26, nimesulide, The risk or severity of hypotension can be increased when Terazosin is combined with Nimesulide.]
[C09AA04, perindopril, Perindopril may increase the hypotensive activities of Terazosin.]
[C02DB02, hydralazine, Terazosin may increase the hypotensive activities of Hydralazine.]
[C03AA03, hydrochlorothiazide, The therapeutic efficacy of Terazosin can be increased when used in combination with Hydrochlorothiazide.]
[C03AA02, hydroflumethiazide, The therapeutic efficacy of Terazosin can be increased when used in combination with Hydroflumethiazide.]
[G04BD06, propiverine, Terazosin may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Propiverine.]
[C02AC06, rilmenidine, The therapeutic efficacy of Rilmenidine can be decreased when used in combination with Terazosin.]
[R02AX02, ibuprofen, The therapeutic efficacy of Terazosin can be decreased when used in combination with Ibuprofen.]
[N01AH03, sufentanil, Sufentanil may decrease the antihypertensive activities of Terazosin.]
[N06AA02, imipramine, Imipramine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Terazosin.]
[L01CD01, paclitaxel, The risk or severity of adverse effects can be increased when Terazosin is combined with Paclitaxel.]
[M03BX02, tizanidine, The therapeutic efficacy of Tizanidine can be decreased when used in combination with Terazosin.]
[C03BA11, indapamide, The therapeutic efficacy of Indapamide can be increased when used in combination with Terazosin.]
[S01BC01, indomethacin, The therapeutic efficacy of Terazosin can be decreased when used in combination with Indomethacin.]
[C02CA02, indoramin, Terazosin may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Indoramin.]
[C07AA01, alprenolol, Alprenolol may increase the orthostatic hypotensive activities of Terazosin.]
[N06AA13, iprindole, Iprindole may decrease the antihypertensive activities of Terazosin.]
[N06AF05, iproniazid, Iproniazid may increase the hypotensive activities of Terazosin.]
[N06AF01, isocarboxazid, Isocarboxazid may increase the hypotensive activities of Terazosin.]
[S01EC03, dorzolamide, Dorzolamide may increase the hypotensive activities of Terazosin.]
[R03CC06, isoetharine, The therapeutic efficacy of Isoetharine can be decreased when used in combination with Terazosin.]
[C09AA16, imidapril, Terazosin may increase the hypotensive activities of Imidapril.]
[N01AB06, isoflurane, Isoflurane may decrease the antihypertensive activities of Terazosin.]
[R03CB01, isoproterenol, The therapeutic efficacy of Isoprenaline can be decreased when used in combination with Terazosin.]
[C05AE02, isosorbide dinitrate, The risk or severity of adverse effects can be increased when Isosorbide dinitrate is combined with Terazosin.]
[C04AA01, isoxsuprine, The therapeutic efficacy of Isoxsuprine can be decreased when used in combination with Terazosin.]
[C02KD01, ketanserin, Terazosin may increase the hypotensive activities of Ketanserin.]
[N05AH03, olanzapine, Olanzapine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Terazosin.]
[M02AA10, ketoprofen, The therapeutic efficacy of Terazosin can be decreased when used in combination with Ketoprofen.]
[C01CA22, arbutamine, The therapeutic efficacy of Arbutamine can be decreased when used in combination with Terazosin.]
[N04BC09, rotigotine, Rotigotine may decrease the antihypertensive activities of Terazosin.]
[M01AE11, tiaprofenic acid, The therapeutic efficacy of Terazosin can be decreased when used in combination with Tiaprofenic acid.]
[C07AG01, labetalol, Labetalol may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Terazosin.]
[C02AA05, deserpidine, Deserpidine may increase the hypotensive activities of Terazosin.]
[C03CC01, ethacrynic acid, The risk or severity of adverse effects can be increased when Etacrynic acid is combined with Terazosin.]
[N04BA01, levodopa, The risk or severity of hypotension and orthostatic hypotension can be increased when Terazosin is combined with Levodopa.]
[C08EX01, lidoflazine, The risk or severity of hypotension can be increased when Terazosin is combined with Lidoflazine.]
[C03DB01, amiloride, The risk or severity of adverse effects can be increased when Amiloride is combined with Terazosin.]
[N02CA07, lisuride, Lisuride may decrease the antihypertensive activities of Terazosin.]
[N06AA07, lofepramine, Lofepramine may decrease the antihypertensive activities of Terazosin.]
[A07DA03, loperamide, The risk or severity of hypotension can be increased when Terazosin is combined with Loperamide.]
[V04CC02, magnesium sulfate, The risk or severity of hypotension can be increased when Terazosin is combined with Magnesium sulfate.]
[V04CX04, mannitol, The risk or severity of adverse effects can be increased when Mannitol is combined with Terazosin.]
[C02BB01, mecamylamine, Mecamylamine may increase the hypotensive activities of Terazosin.]
[M02AA18, meclofenamic acid, The therapeutic efficacy of Terazosin can be decreased when used in combination with Meclofenamic acid.]
[C01CA11, mephentermine, The therapeutic efficacy of Terazosin can be decreased when used in combination with Mephentermine.]
[N03AA01, mephobarbital, Methylphenobarbital may increase the hypotensive activities of Terazosin.]
[N05AX13, paliperidone, Terazosin may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Paliperidone.]
[C01CA09, metaraminol, The therapeutic efficacy of Metaraminol can be decreased when used in combination with Terazosin.]
[N06BA03, methamphetamine, The therapeutic efficacy of Terazosin can be decreased when used in combination with Metamfetamine.]
[S01EC05, methazolamide, The risk or severity of adverse effects can be increased when Methazolamide is combined with Terazosin.]
[G02CB05, metergoline, Metergoline may decrease the antihypertensive activities of Terazosin.]
[N05CA15, methohexital, Methohexital may increase the hypotensive activities of Terazosin.]
[N02BG08, ziconotide, The risk or severity of hypotension can be increased when Terazosin is combined with Ziconotide.]
[N05AA02, methotrimeprazine, Terazosin may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Methotrimeprazine.]
[C01CA10, methoxamine, The therapeutic efficacy of Methoxamine can be decreased when used in combination with Terazosin.]
[N02BG09, methoxyflurane, Methoxyflurane may decrease the antihypertensive activities of Terazosin.]
[C03AA08, methyclothiazide, The therapeutic efficacy of Terazosin can be increased when used in combination with Methyclothiazide.]
[C02AB01, methyldopa, The therapeutic efficacy of Methyldopa can be decreased when used in combination with Terazosin.]
[V04CG05, methylene blue, Methylene blue may increase the hypotensive activities of Terazosin.]
[G02AB01, methylergonovine, Methylergometrine may decrease the antihypertensive activities of Terazosin.]
[N06BA04, methylphenidate, Methylphenidate may decrease the antihypertensive activities of Terazosin.]
[N02CA04, methysergide, Methysergide may decrease the antihypertensive activities of Terazosin.]
[C03BA08, metolazone, Metolazone may increase the hypotensive activities of Terazosin.]
[C07AB02, metoprolol, Metoprolol may increase the orthostatic hypotensive activities of Terazosin.]
[N06AX03, mianserin, Mianserin may decrease the antihypertensive activities of Terazosin.]
[N02BB03, aminopyrine, The therapeutic efficacy of Terazosin can be decreased when used in combination with Aminophenazone.]
[C01CA17, midodrine, The therapeutic efficacy of Midodrine can be decreased when used in combination with Terazosin.]
[C09CA03, valsartan, Valsartan may increase the hypotensive activities of Terazosin.]
[D11AX01, minoxidil, Minoxidil may increase the hypotensive activities of Terazosin.]
[N06BA12, lisdexamfetamine, The therapeutic efficacy of Terazosin can be decreased when used in combination with Lisdexamfetamine.]
[L03AC01, aldesleukin, The risk or severity of adverse effects can be increased when Aldesleukin is combined with Terazosin.]
[C01DX12, molsidomine, Molsidomine may increase the hypotensive activities of Terazosin.]
[C01BD01, amiodarone, The risk or severity of hypotension can be increased when Terazosin is combined with Amiodarone.]
[N06AA09, amitriptyline, Amitriptyline may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Terazosin.]
[N02AA01, morphine, The risk or severity of adverse effects can be increased when Morphine is combined with Terazosin.]
[N05CA02, amobarbital, Amobarbital may increase the hypotensive activities of Terazosin.]
[G04CA04, silodosin, The risk or severity of orthostatic hypotension and dizziness can be increased when Terazosin is combined with Silodosin.]
[N06AA17, amoxapine, Amoxapine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Terazosin.]
[C07AA12, nadolol, Nadolol may increase the orthostatic hypotensive activities of Terazosin.]
[N04BC04, ropinirole, The risk or severity of adverse effects can be increased when Ropinirole is combined with Terazosin.]
[S01GA01, naphazoline, The therapeutic efficacy of Naphazoline can be decreased when used in combination with Terazosin.]
[N06BA01, amphetamine, The therapeutic efficacy of Terazosin can be decreased when used in combination with Amphetamine.]
[M02AA12, naproxen, The therapeutic efficacy of Terazosin can be decreased when used in combination with Naproxen.]
[N06AX21, duloxetine, The risk or severity of orthostatic hypotension and syncope can be increased when Terazosin is combined with Duloxetine.]
[N04BX01, tolcapone, The risk or severity of adverse effects can be increased when Tolcapone is combined with Terazosin.]
[N01AH06, remifentanil, Remifentanil may decrease the antihypertensive activities of Terazosin.]
[C01CX08, levosimendan, The risk or severity of adverse effects can be increased when Levosimendan is combined with Terazosin.]
[N05AX14, iloperidone, Terazosin may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Iloperidone.]
[J02AA01, amphotericin B, The risk or severity of adverse effects can be increased when Amphotericin B is combined with Terazosin.]
[C09CA07, telmisartan, Telmisartan may increase the hypotensive activities of Terazosin.]
[N06AF02, nialamide, Nialamide may increase the hypotensive activities of Terazosin.]
[C08CA04, nicardipine, Nicardipine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Terazosin.]
[C04AE02, nicergoline, Nicergoline may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Terazosin.]
[C08CA05, nifedipine, The risk or severity of hypotension can be increased when Terazosin is combined with Nifedipine.]
[M02AA17, niflumic acid, The therapeutic efficacy of Terazosin can be decreased when used in combination with Niflumic acid.]
[V03AB22, amyl nitrite, The risk or severity of adverse effects can be increased when Terazosin is combined with Amyl Nitrite.]
[C08CA06, nimodipine, The risk or severity of hypotension can be increased when Terazosin is combined with Nimodipine.]
[C08CA07, nisoldipine, The risk or severity of hypotension can be increased when Terazosin is combined with Nisoldipine.]
[C08CA08, nitrendipine, The risk or severity of hypotension can be increased when Terazosin is combined with Nitrendipine.]
[R07AX01, nitric oxide, The risk or severity of adverse effects can be increased when Nitric Oxide is combined with Terazosin.]
[N04BC05, pramipexole, The risk or severity of adverse effects can be increased when Pramipexole is combined with Terazosin.]
[C02DD01, nitroprusside, Nitroprusside may increase the hypotensive activities of Terazosin.]
[N01AX13, nitrous oxide, Nitrous oxide may decrease the antihypertensive activities of Terazosin.]
[C01CA03, norepinephrine, The therapeutic efficacy of Norepinephrine can be decreased when used in combination with Terazosin.]
[C02KX01, bosentan, Bosentan may increase the hypotensive activities of Terazosin.]
[N06AA10, nortriptyline, Nortriptyline may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Terazosin.]
[G02CA02, nylidrin, The therapeutic efficacy of Nylidrin can be decreased when used in combination with Terazosin.]
[N06AA05, opipramol, Opipramol may decrease the antihypertensive activities of Terazosin.]
[R03CB03, metaproterenol, The therapeutic efficacy of Orciprenaline can be decreased when used in combination with Terazosin.]
[G04CA02, tamsulosin, Tamsulosin may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Terazosin.]
[C07AA02, oxprenolol, Oxprenolol may increase the orthostatic hypotensive activities of Terazosin.]
[C01DX03, oxyfedrine, The therapeutic efficacy of Oxyfedrine can be decreased when used in combination with Terazosin.]
[S01GA04, oxymetazoline, The therapeutic efficacy of Terazosin can be decreased when used in combination with Oxymetazoline.]
[S01BC02, oxyphenbutazone, The therapeutic efficacy of Terazosin can be decreased when used in combination with Oxyphenbutazone.]
[N05AH05, asenapine, Terazosin may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Asenapine.]
[G04BE02, papaverine, The risk or severity of adverse effects can be increased when Papaverine is combined with Terazosin.]
[C02KC01, pargyline, Pargyline may increase the hypotensive activities of Terazosin.]
[C07AA23, penbutolol, Penbutolol may increase the orthostatic hypotensive activities of Terazosin.]
[N05AG03, penfluridol, The risk or severity of hypotension can be increased when Terazosin is combined with Penfluridol.]
[N05CA01, pentobarbital, Pentobarbital may increase the hypotensive activities of Terazosin.]
[C04AD03, pentoxifylline, Pentoxifylline may increase the hypotensive activities of Terazosin.]
[N04BC02, pergolide, The therapeutic efficacy of Pergolide can be decreased when used in combination with Terazosin.]
[C08EX02, perhexiline, The risk or severity of hypotension can be increased when Terazosin is combined with Perhexiline.]
[N06AF03, phenelzine, Phenelzine may increase the hypotensive activities of Terazosin.]
[N03AA02, phenobarbital, Phenobarbital may increase the hypotensive activities of Terazosin.]
[C04AX02, phenoxybenzamine, Phenoxybenzamine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Terazosin.]
[A08AA01, phentermine, The therapeutic efficacy of Terazosin can be decreased when used in combination with Phentermine.]
[V03AB36, phentolamine, Phentolamine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Terazosin.]
[M02AA01, phenylbutazone, The therapeutic efficacy of Terazosin can be decreased when used in combination with Phenylbutazone.]
[S01GA05, phenylephrine, The therapeutic efficacy of Phenylephrine can be decreased when used in combination with Terazosin.]
[R01BA01, phenylpropanolamine, The therapeutic efficacy of Phenylpropanolamine can be decreased when used in combination with Terazosin.]
[C08CX01, mibefradil, The risk or severity of hypotension can be increased when Terazosin is combined with Mibefradil.]
[C07AA03, pindolol, Pindolol may increase the orthostatic hypotensive activities of Terazosin.]
[C09CA02, eprosartan, Eprosartan may increase the hypotensive activities of Terazosin.]
[S01BC06, piroxicam, The therapeutic efficacy of Terazosin can be decreased when used in combination with Piroxicam.]
[N02CX01, pizotyline, Terazosin may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Pizotifen.]
[C09CA04, irbesartan, Irbesartan may increase the hypotensive activities of Terazosin.]
[C03AA05, polythiazide, The therapeutic efficacy of Terazosin can be increased when used in combination with Polythiazide.]
[C07AB01, practolol, Practolol may increase the orthostatic hypotensive activities of Terazosin.]
[C02CA01, prazosin, The risk or severity of hypotension can be increased when Prazosin is combined with Terazosin.]
[C01DX02, prenylamine, The risk or severity of hypotension can be increased when Terazosin is combined with Prenylamine.]
[N03AA03, primidone, Primidone may increase the hypotensive activities of Terazosin.]
[S01HA05, procaine, Procaine may increase the hypotensive activities of Terazosin.]
[L01XB01, procarbazine, Procarbazine may increase the hypotensive activities of Terazosin.]
[N05AA03, promazine, Promazine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Terazosin.]
[C01BC03, propafenone, Propafenone may increase the orthostatic hypotensive activities of Terazosin.]
[N05AC01, periciazine, Terazosin may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Periciazine.]
[N05CM06, propiomazine, Propiomazine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Terazosin.]
[N01AX10, propofol, Propofol may decrease the antihypertensive activities of Terazosin.]
[C07AA05, propranolol, Propranolol may increase the orthostatic hypotensive activities of Terazosin.]
[N02CC04, rizatriptan, Rizatriptan may decrease the antihypertensive activities of Terazosin.]
[B01AC09, epoprostenol, Epoprostenol may increase the hypotensive activities of Terazosin.]
[N06AA11, protriptyline, Protriptyline may decrease the antihypertensive activities of Terazosin.]
[R01BA02, pseudoephedrine, The therapeutic efficacy of Terazosin can be decreased when used in combination with Pseudoephedrine.]
[N05AX12, aripiprazole, Terazosin may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Aripiprazole.]
[C01BA01, quinidine, Quinidine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Terazosin.]
[P01BC01, quinine, Quinine may increase the hypotensive activities of Terazosin.]
[C02AA01, rescinnamine, Rescinnamine may decrease the antihypertensive activities of Terazosin.]
[C02AA02, reserpine, Reserpine may increase the hypotensive activities of Terazosin.]
[R03AC05, rimiterol, The therapeutic efficacy of Rimiterol can be decreased when used in combination with Terazosin.]
[G02CA01, ritodrine, The therapeutic efficacy of Ritodrine can be decreased when used in combination with Terazosin.]
[N02BA05, salicylamide, The therapeutic efficacy of Terazosin can be decreased when used in combination with Salicylamide.]
[A07EC01, sulfasalazine, The therapeutic efficacy of Terazosin can be decreased when used in combination with Sulfasalazine.]
[S01BC08, salicylic acid, The therapeutic efficacy of Terazosin can be decreased when used in combination with Salicylic acid.]
[N05CA06, secobarbital, Secobarbital may increase the hypotensive activities of Terazosin.]
[N04BD01, selegiline, Selegiline may increase the hypotensive activities of Terazosin.]
[L01FA03, obinutuzumab, Terazosin may increase the hypotensive activities of Obinutuzumab.]
[C07AA07, sotalol, Sotalol may increase the orthostatic hypotensive activities of Terazosin.]
[C03DA01, spironolactone, The risk or severity of adverse effects can be increased when Spironolactone is combined with Terazosin.]
[C01DA14, isosorbide mononitrate, The risk or severity of adverse effects can be increased when Isosorbide mononitrate is combined with Terazosin.]
